Mood Disorders Therapeutics
1. Abilify patent expiration
Treatment: Treatment of irritability associated with autistic disorder; Treatment of schizophrenia including maintaining stability in patients with schizophrenia; Treatment of schizophrenia; Treatment of major d...
ABILIFY's oppositions filed in EPO
ABILIFY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(3 years ago) | |
| US5006528 | OTSUKA | Carbostyril derivatives |
Oct, 2014
(11 years ago) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(3 years ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(3 years ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(2 years ago) | |
|
US8642600 (Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(3 years ago) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(1 year, 1 month from now) | |
| US8518421 | OTSUKA | Flashmelt oral dosage formulation |
Jan, 2021
(4 years ago) | |
| US6977257 | OTSUKA | Aripiprazole oral solution |
Apr, 2022
(3 years ago) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(6 months from now) | |
|
US5006528 (Pediatric) | OTSUKA | Carbostyril derivatives |
Apr, 2015
(10 years ago) | |
|
US8518421 (Pediatric) | OTSUKA | Flashmelt oral dosage formulation |
Jul, 2021
(4 years ago) | |
| US9358207 | OTSUKA | Flashmelt oral dosage formulation |
Apr, 2020
(5 years ago) | |
|
US8642760 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 years ago) | |
|
US8580796 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 years ago) | |
|
US6977257 (Pediatric) | OTSUKA | Aripiprazole oral solution |
Oct, 2022
(3 years ago) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 6 months ago) | |
|
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(1 year, 24 days ago) | |
| US7115587 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(1 year, 5 months ago) | |
| US7550445 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(1 year, 5 months ago) | |
|
US7115587 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(11 months ago) | |
|
US7550445 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| New Indication(I-616) | Nov 19, 2012 |
| New Indication(I-633) | Feb 16, 2014 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Dosage: TABLET; TABLET, ORALLY DISINTEGRATING; INJECTABLE; SOLUTION
How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage
ABILIFY family patents
2. Barhemsys patent expiration
Treatment: Prevention and treatment of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting; Prevention of post-operative nausea and vomiting
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12329740 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(12 years from now) | |
| US12194022 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(5 years from now) | |
| US12005042 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(12 years from now) | |
| US11357753 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(12 years from now) | |
| US9545426 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(5 years from now) | |
| US9889118 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(5 years from now) | |
| US9084765 | ACACIA | Use of amisulpride as an anti-emetic |
Feb, 2034
(8 years from now) | |
| US10525033 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 27 February, 2024
Market Authorisation Date: 26 February, 2020
Dosage: SOLUTION
More Information on Dosage
BARHEMSYS family patents
3. Geodon patent
expiration
Treatment: Treatment of bipolar disorder
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6150366 | VIATRIS | Ziprasidone formulations |
May, 2019
(6 years ago) | |
| US5312925 | VIATRIS | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(13 years ago) | |
| US6245766 | VIATRIS | Method of treating psychiatric conditions |
Dec, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 February, 2001
Dosage: CAPSULE
How can I launch a generic of GEODON before it's drug patent expiration?
More Information on Dosage
GEODON family patents
4. Geodon patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6399777 | VIATRIS | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(8 years ago) | |
| US6232304 | VIATRIS | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(8 years ago) | |
| US6110918 | VIATRIS | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
Mar, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
Drugs and Companies using ZIPRASIDONE MESYLATE ingredient
Market Authorisation Date: 21 June, 2002
Dosage: POWDER
More Information on Dosage
GEODON family patents
5. Geodon patent expiration
Treatment: Treatment of bipolar disorder; Treatment of psychosis; Treatment of neuroleptic diseases
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7175855 | PFIZER INC | Ziprasidone suspension |
May, 2020
(5 years ago) | |
| US6245766 | PFIZER INC | Method of treating psychiatric conditions |
Dec, 2018
(7 years ago) | |
| US6150366 | PFIZER INC | Ziprasidone formulations |
May, 2019
(6 years ago) | |
| US5312925 | PFIZER INC | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(13 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 March, 2006
Dosage: SUSPENSION
How can I launch a generic of GEODON before it's drug patent expiration?
More Information on Dosage
GEODON family patents
6. Latuda patent expiration
Treatment: Treatment of major depressive episodes associated with bipolar i disorder; Treatment of schizophrenia; Treatment of bipolar depression with improvement in attention function in bipolar disorder; Treat...
LATUDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5532372 | SUNOVION PHARMS INC | Imide derivatives, and their production and use |
Jul, 2018
(7 years ago) | |
| USRE45573 | SUNOVION PHARMS INC | Process for producing imide compound |
Jun, 2025
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5532372 | SUNOVION PHARMS INC | Imide derivatives, and their production and use |
Jul, 2018
(7 years ago) | |
| US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(1 year, 10 months ago) | |
|
US5532372 (Pediatric) | SUNOVION PHARMS INC | Imide derivatives, and their production and use |
Jan, 2019
(7 years ago) | |
| US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(4 months from now) | |
| US9827242 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(5 years from now) | |
| US9174975 | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Feb, 2024
(1 year, 10 months ago) | |
| US9259423 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(5 years from now) | |
|
US9174975 (Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(1 year, 4 months ago) | |
| US8729085 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(4 months from now) | |
| US9907794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(4 months from now) | |
| US8883794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(4 months from now) | |
|
US8883794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(10 months from now) | |
|
US8729085 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(10 months from now) | |
|
US9907794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(10 months from now) | |
|
US9259423 (Pediatric) | SUNOVION PHARMS INC | Method of treatment for mental disorders |
Nov, 2031
(5 years from now) | |
|
USRE45573 (Pediatric) | SUNOVION PHARMS INC | Process for producing imide compound |
Dec, 2025
(17 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| New Indication(I-674) | Jun 28, 2016 |
| M(M-195) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Dosage: TABLET
How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage
LATUDA family patents
7. Pristiq patent expiration
Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)
PRISTIQ's oppositions filed in EPO
PRISTIQ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Mar, 2022
(3 years ago) | |
| US8269040 | PF PRISM CV | Derivatives of venlafaxine and methods of preparing and using the same |
Jul, 2027
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Feb, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 01, 2013 |
| New Indication(I-675) | Feb 14, 2016 |
| M(M-222) | Feb 06, 2021 |
Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient
NCE-1 date: 01 March, 2012
Market Authorisation Date: 20 August, 2014
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of PRISTIQ before it's drug patent expiration?
More Information on Dosage
PRISTIQ family patents
8. Rexulti patent expiration
Treatment: Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia; Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
REXULTI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7888362 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 months from now) | |
| USRE48059 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8349840 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 months from now) | |
| US9839637 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 months from now) | |
| US8618109 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 months from now) | |
| US10307419 | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Oct, 2032
(6 years from now) | |
|
US9839637 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(9 months from now) | |
|
US8618109 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(9 months from now) | |
|
US7888362 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(9 months from now) | |
|
US8349840 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(9 months from now) | |
|
USRE48059 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Jun, 2029
(3 years from now) | |
|
US10307419 (Pediatric) | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Apr, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-186) | Sep 23, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2020 |
| New Patient Population(NPP) | Dec 27, 2024 |
| New Indication(I-913) | May 10, 2026 |
| Pediatric Exclusivity(PED) | Nov 10, 2026 |
| M(M-14) | May 08, 2027 |
| M(M-315) | May 09, 2028 |
Drugs and Companies using BREXPIPRAZOLE ingredient
NCE-1 date: 10 November, 2025
Market Authorisation Date: 10 July, 2015
Dosage: TABLET
How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage
REXULTI family patents
9. Saphris patent expiration
Treatment: Method of treating schizophrenia and bipolar disorder; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: maintenance monotherapy in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7741358 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(2 months from now) | |
| US8022228 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5763476 (Pediatric) | ALLERGAN | Sublingual or buccal pharmaceutical composition |
Dec, 2020
(5 years ago) | |
| US5763476 | ALLERGAN | Sublingual or buccal pharmaceutical composition |
Jun, 2020
(5 years ago) | |
|
US7741358 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(8 months from now) | |
|
US8022228 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-628) | Sep 03, 2013 |
| New Indication(I-629) | Sep 03, 2013 |
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2014 |
| M(M-158) | Mar 12, 2018 |
| New Patient Population(NPP) | Mar 12, 2018 |
| Pediatric Exclusivity(PED) | Sep 12, 2018 |
| New Dosing Schedule(D-166) | Jan 13, 2020 |
| New Indication(I-597) | Jan 13, 2020 |
Drugs and Companies using ASENAPINE MALEATE ingredient
NCE-1 date: 12 September, 2017
Market Authorisation Date: 12 March, 2015
Dosage: TABLET
How can I launch a generic of SAPHRIS before it's drug patent expiration?
More Information on Dosage
SAPHRIS family patents
10. Trintellix patent expiration
Treatment: Method of treating an affective disorder such as depression; Method of treating depression or major depressive disorder; Use in the treatment of major depressive disorder to improve processing speed, ...
TRINTELLIX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7144884 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Jun, 2026
(5 months from now) | |
| US8722684 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8476279 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Oct, 2022
(3 years ago) | |
| US8969355 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 5 months from now) | |
| US9125910 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 5 months from now) | |
| US9227946 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 5 months from now) | |
| US11458134 | TAKEDA PHARMS USA | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 5 months from now) | |
| US9125909 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 5 months from now) | |
| US9125908 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 5 months from now) | |
| US9861630 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(1 year, 5 months from now) | |
| US9278096 | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Mar, 2032
(6 years from now) | |
|
US8722684 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2031
(5 years from now) | |
|
US7144884 (Pediatric) | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Dec, 2026
(11 months from now) | |
|
US8969355 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Dec, 2027
(1 year, 11 months from now) | |
|
US9227946 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Dec, 2027
(1 year, 11 months from now) | |
|
US9125908 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(1 year, 11 months from now) | |
|
US9125909 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(1 year, 11 months from now) | |
|
US9125910 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(1 year, 11 months from now) | |
|
US9861630 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(1 year, 11 months from now) | |
|
US9278096 (Pediatric) | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Sep, 2032
(6 years from now) | |
|
US11458134 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2018 |
| M(M-227) | May 02, 2021 |
| M(M-234) | Oct 19, 2021 |
| M(M-267) | Nov 13, 2023 |
| M(M-187) | Jan 22, 2024 |
| M(M-232) | Aug 23, 2026 |
| Pediatric Exclusivity(PED) | Feb 23, 2027 |
Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient
NCE-1 date: 23 February, 2026
Market Authorisation Date: 30 September, 2013
Dosage: TABLET
How can I launch a generic of TRINTELLIX before it's drug patent expiration?
More Information on Dosage
TRINTELLIX family patents
11. Viibryd patent expiration
Treatment: Treatment of major depressive disorder (mdd)
VIIBRYD IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8673921 | ABBVIE | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5532241 | ABBVIE | Piperidines and piperazines |
Sep, 2014
(11 years ago) | |
|
US8193195 (Pediatric) | ABBVIE | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(3 years ago) | |
| US7834020 | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(3 years ago) | |
| US8193195 | ABBVIE | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(3 years ago) | |
| US8236804 | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun, 2022
(3 years ago) | |
|
US7834020 (Pediatric) | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(3 years ago) | |
|
US8236804 (Pediatric) | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(3 years ago) | |
|
US8673921 (Pediatric) | ABBVIE | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2016 |
| New Dosing Schedule(D-146) | Mar 16, 2018 |
| M(M-254) | Jan 31, 2023 |
| Pediatric Exclusivity(PED) | Jul 31, 2023 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 21 January, 2011
Dosage: TABLET
How can I launch a generic of VIIBRYD before it's drug patent expiration?
More Information on Dosage
VIIBRYD family patents
12. Vraylar patent expiration
Treatment: Adjunctive therapy to antidepressants for the treatment of major depressive disorder; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine; Treatme...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7737142 | ABBVIE | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(3 years from now) | |
| US7943621 | ABBVIE | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE49110 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| USRE49302 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| USRE47350 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 17, 2020 |
| M(M-213) | Nov 09, 2020 |
| New Indication(I-798) | May 24, 2022 |
| New Indication(I-904) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
NCE-1 date: 18 September, 2019
Market Authorisation Date: 17 September, 2015
Dosage: CAPSULE
How can I launch a generic of VRAYLAR before it's drug patent expiration?
More Information on Dosage
VRAYLAR family patents
13. Zulresso patent expiration
Treatment: Method of treating postpartum depression
ZULRESSO's oppositions filed in EPO
Can you believe ZULRESSO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940156 | SAGE THERAP | Neuroactive steroids, compositions, and uses thereof |
Mar, 2037
(11 years from now) | |
| US10251894 | SAGE THERAP | Anticonvulsant activity of steroids |
Nov, 2033
(7 years from now) | |
| US8410077 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9750822 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US7635773 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US10322139 | SAGE THERAP | Neuroactive steroid formulations and methods of treating CNS disorders |
Jan, 2033
(7 years from now) | |
| US9200088 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US10117951 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| New Patient Population(NPP) | Jun 16, 2025 |
Drugs and Companies using BREXANOLONE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Dosage: SOLUTION
More Information on Dosage
ZULRESSO family patents
14. Zurzuvae patent expiration
Treatment: Method of treating postpartum depression
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512165 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(8 years from now) | |
| US11236121 | BIOGEN INC | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid |
Aug, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11884696 | BIOGEN INC | Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid |
Aug, 2037
(11 years from now) | |
| US10342810 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(8 years from now) | |
| US10172871 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2028 |
Drugs and Companies using ZURANOLONE ingredient
NCE-1 date: 01 November, 2027
Market Authorisation Date: 31 October, 2023
Dosage: CAPSULE
More Information on Dosage
ZURZUVAE family patents